Topics

Fennec Pharmaceuticals Inc FRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $106

12:31 EST 15 Jan 2020 | BioPortfolio Report Blog

Fennec Pharmaceuticals Inc FRX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Highlights


Fennec Pharmaceuticals Inc Fennec formerly Adherex Technologies Inc. develops drugs for cancer treatments. It focuses on the discovery and development of new treatments for on tumor cells and tumor blood vessels. Fennec has one late stage clinical product Pedmark which is a chemical reducing agent undergoing two Phase III clinical trials for the prevention of cisplatin induced hearing loss and ototoxicity in children. The company has licensing agreements with Oregon Health Science University for development of its drug candidates. Fennec is headquartered in Durham, North Carolina, the US.


Fennec Pharmaceuticals Inc Key Recent Developments


Aug 09,2019: Fennec provides business update and announces second quarter 2019 financial results

May 09,2019: Fennec provides business update and announces first quarter 2019 financial results

Mar 13,2019: Fennec provides business update and announces fiscal year 2018 financial results

Nov 13,2018: Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results

Aug 13,2018: Fennec provides business update and announces second quarter 2018 financial results


Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Note: Some sections may be missing if data is unavailable for the company

Original Article: Fennec Pharmaceuticals Inc FRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $106

NEXT ARTICLE

More From BioPortfolio on "Fennec Pharmaceuticals Inc FRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $106"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...